comprehensive -WSS

comprehensive

author：fashion 2025-10-01 01:49:13 - browse：62363

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Elizabeth Holmes banned from government health programs

focus

WSS

Why medical students are struggling with mental health

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Think you might have Covid

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

A daunting task: navigating dual Medicare, Medicaid eligibility

Gain of function research would be limited under House proposal

hotspot

comprehensive

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The tragedy of Johnson & Johnson’s Covid vaccine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Prior authorization will have to move faster under new Biden rule

Hollywood unions extend contract negotiations for actors

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

The cancer drug shortage isn’t new — and neither are the solutions

Astellas still sees hope in its gene therapy after four deaths

Continuity nursing helped my family in our darkest PICU moments

Elizabeth Holmes banned from government health programs

focus

How digital therapeutics firms are pivoting after Pear's bankruptcy

Poor hospice wound care hurts patients and families

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Childhood cancer progress stalls for Black, Hispanic kids: Report

Why doctors need education on FDA device approval process

Does good food count as health care? Study aims to find out

hotspot

focus

focus

hotspot